Last reviewed · How we verify
Lecanemab SC
Lecanemab is a monoclonal antibody that binds to amyloid-beta protofibrils and promotes their clearance from the brain.
Lecanemab is a monoclonal antibody that binds to amyloid-beta protofibrils and promotes their clearance from the brain. Used for Mild cognitive impairment or mild dementia stage of Alzheimer's disease.
At a glance
| Generic name | Lecanemab SC |
|---|---|
| Also known as | BAN2401 |
| Sponsor | Eisai Inc. |
| Drug class | Monoclonal antibody (anti-amyloid-beta) |
| Target | Amyloid-beta protofibrils |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Lecanemab targets soluble amyloid-beta protofibrils, which are believed to be toxic intermediates in Alzheimer's disease pathogenesis. By binding to these protofibrils, the antibody facilitates their removal through microglial phagocytosis and peripheral clearance. This mechanism aims to slow cognitive decline in early Alzheimer's disease by reducing amyloid burden in the brain.
Approved indications
- Mild cognitive impairment or mild dementia stage of Alzheimer's disease
Common side effects
- Amyloid-related imaging abnormalities (ARIA) - microhemorrhages
- Amyloid-related imaging abnormalities (ARIA) - microinfarcts
- Infusion reactions
- Headache
Key clinical trials
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease (PHASE2)
- A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (PHASE3)
- A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants (PHASE1)
- A Study of Subcutaneous Lecanemab in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lecanemab SC CI brief — competitive landscape report
- Lecanemab SC updates RSS · CI watch RSS
- Eisai Inc. portfolio CI